Avita Medical, Inc.
RCEL
Positions held
Your positionsRCEL isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $412.25M | Enterprise value | $449.60M | Trailing P/E | — | Forward P/E | -31.99 |
| PEG | — | Price / book | -14.81 | Beta | 1.99 | Dividend yield | 0.00% |
| Revenue growth | 17.8% | Earnings growth | — | Gross margin | 81.6% | Operating margin | -31.6% |
| Profit margin | -57.0% | ROE | — | ROA | -41.6% | Debt / equity | — |
| Current ratio | 0.41 | Free cash flow | -$13.35M | Analyst recommendation | none | Mean target | $12.06 |
| 52w high | $13.50 | 52w low | $3.22 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $21.7M | $19.3M | $17.6M | $17.1M | $18.4M |
| Op margin | -31.6% | -45.7% | -59.1% | -53.6% | -60.5% |
| Net income | -$7.7M | -$10.6M | -$11.6M | -$13.2M | -$9.9M |
| Gross margin | 81.9% | 81.7% | 81.2% | 81.3% | 81.2% |
| Gross profit | $17.8M | $15.7M | $14.3M | $13.9M | $14.9M |
| Operating income | -$6.9M | -$8.8M | -$10.4M | -$9.2M | -$11.1M |
- Revenue +13% vs prior quarter ($22M vs $19M).
- Gross margin 81.9% (was 81.7% prior quarter).
- Operating margin expanded to -31.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $71.6M | $64.3M | $50.1M | $34.4M |
| Op margin | -59.4% | -88.1% | -85.1% | -79.9% |
| Net income | -$48.6M | -$61.8M | -$35.4M | -$26.7M |
| Gross margin | 82.1% | 85.8% | 84.5% | 82.4% |
| Gross profit | $58.8M | $55.2M | $42.4M | $28.4M |
| Operating income | -$42.5M | -$56.6M | -$42.7M | -$27.5M |
Headlines — positive tone
• [OK · fundamentals] All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
News
2026-10-01 · AVITA Medical (RCEL) Stock Sees Fair Value Lift After PermeaDerm Data And Q2 Beat
2026-09-02 · AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
2026-08-31 · All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
2026-08-25 · AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases
2026-08-24 · Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
2026-08-19 · Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
2026-08-16 · Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
2026-08-16 · Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds
2026-08-13 · AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript
2026-08-09 · AVITA Medical to Host Investor Webinar Briefing
2026-08-07 · AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
Price (daily)
Full chart · RSI · MACD · patterns